GlobalData on MSN16h
FDA grants approval to commence trial of R3 Vascular’s scaffoldThe trial is anticipated to commence in Q1 2025 and will enrol 264 subjects at up to 60 clinical sites worldwide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback